Malta - engelska - Medicines Authority

sanofi pasteur 14 espace henry vallée , 69007 lyon, france - tetanus toxoid, diphtheria toxoid, haemophilus type, b polysaccharide, polyribosylribitol phosphate, conjugated to, as carrier, protein, bordetella pertussis - powder and suspension for suspension for injection - diphtheria toxoid haemophilus type b polysaccharide (polyribosylribitol phosphate) conjugated to tetanus toxoid as carrier protein 10 µg bordetella pertussis 4 iu tetanus toxoid 60 iu - vaccines

Kanada - engelska - Health Canada

aventis pasteur limited - diphtheria toxoid adsorbed; tetanus toxoid adsorbed - liquid - 25lf; 5lf - diphtheria toxoid adsorbed 25lf; tetanus toxoid adsorbed 5lf - toxoids

Australien - engelska - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - diphtheria toxoid, quantity: 2 iu; pertussis filamentous haemagglutinin, quantity: 5 microgram; pertussis toxoid, quantity: 2.5 microgram; pertussis fimbriae 2 + 3, quantity: 5 microgram; pertactin, quantity: 3 microgram; tetanus toxoid, quantity: 20 iu - injection, suspension - excipient ingredients: glutaral; formaldehyde; phenoxyethanol; water for injections; aluminium phosphate - adacel is indicated for active immunisation against tetanus, diphtheria and pertussis in persons aged 10 years and over as a booster following primary immunisation. adacel may be administered during pregnancy for prevention of pertussis in young infants via transplacental antibody transfer from the pregnant woman to the fetus.

USA - engelska - NLM (National Library of Medicine)

mcm vaccine co. - corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (unii: irh51qn26h) (corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) - unii:irh51qn26h), clostridium tetani toxoid antigen (formaldehyde inactivated) (unii: k3w1n8yp13) (clostridium tetani toxoid antigen (formaldehyde inactivated) - unii:k3w1n8yp13), bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (unii: f4tn0ipy37) (bordetella pertussis toxoid antigen (glutaraldehyde inactivated) - unii:f4tn0ipy37), - vaxelis™ is a vaccine indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis b, and invasive disease due to haemophilus influenzae (h. influenzae ) type b. vaxelis is approved for use as a 3-dose series in children 6 weeks through 4 years of age (prior to the 5th birthday). do not administer vaxelis to anyone with a history of a severe allergic reaction (e.g., anaphylaxis) to a previous dose of vaxelis, any ingredient of vaxelis, or any other diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, inactivated poliovirus vaccine, hepatitis b vaccine, or h. influenzae type b vaccine [see description (11) .] do not administer vaxelis to anyone with a history of encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) within 7 days of a previous dose of a pertussis-containing vaccine, that is not attributable to another identifiable cause. do not administer vaxelis to anyone with a history of progressive neurologic disorder, includ

USA - engelska - NLM (National Library of Medicine)

msp vaccine company - corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (unii: irh51qn26h) (corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) - unii:irh51qn26h), clostridium tetani toxoid antigen (formaldehyde inactivated) (unii: k3w1n8yp13) (clostridium tetani toxoid antigen (formaldehyde inactivated) - unii:k3w1n8yp13), bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (unii: f4tn0ipy37) (bordetella pertussis toxoid antigen (glutaraldehyde inactivated) - unii:f4tn0ipy37 - vaxelis® is a vaccine indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis b, and invasive disease due to haemophilus influenzae (h. influenzae ) type b. vaxelis is approved for use as a 3-dose series in children 6 weeks through 4 years of age (prior to the 5th birthday). do not administer vaxelis to anyone with a history of a severe allergic reaction (e.g., anaphylaxis) to a previous dose of vaxelis, any ingredient of vaxelis, or any other diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, inactivated poliovirus vaccine, hepatitis b vaccine, or h. influenzae type b vaccine [see description (11) .] do not administer vaxelis to anyone with a history of encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) within 7 days of a previous dose of a pertussis-containing vaccine, that is not attributable to another identifiable cause. do not administer vaxelis to anyone with a history of progressive neurologic disorder, inclu

Kanada - engelska - Health Canada

sanofi pasteur limited - filamentous haemagglutinin; pertussis toxoid; pertactin; tetanus toxoid; fimbriae types 2 and 3 (fim); poliovirus type 1 mahoney (inactivated); poliovirus type 2 mef1 (inactivated); poliovirus type 3 saukett (inactivated); diphtheria toxoid - suspension - 5mcg; 2.5mcg; 3mcg; 5lf; 5mcg; 29unit; 7unit; 26unit; 2lf - filamentous haemagglutinin 5mcg; pertussis toxoid 2.5mcg; pertactin 3mcg; tetanus toxoid 5lf; fimbriae types 2 and 3 (fim) 5mcg; poliovirus type 1 mahoney (inactivated) 29unit; poliovirus type 2 mef1 (inactivated) 7unit; poliovirus type 3 saukett (inactivated) 26unit; diphtheria toxoid 2lf - vaccines

Irland - engelska - HPRA (Health Products Regulatory Authority)

sanofi pasteur - purified diphtheria toxoid ph. eur.; purified tetanus toxoid; adsorbed purified pertussis toxoid; adsorbed purified filamentous haemagglutinin; inactivated poliomyelitis virus ph. eur; inactivated type 1 poliovirus; inactivated type 2 poliovirus; inactivated type 3 poliovirus; haemophilus influenzae type b, conjugate with tetanus protein - powder for suspension for injection - 0.5 millilitre(s) - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus

Kanada - engelska - Health Canada

sanofi pasteur limited - pertussis toxoid; filamentous haemagglutinin; fimbriae; pertactin; diphtheria toxoid; tetanus toxoid; inactivated poliomyelitis vaccine (d.c.o.) type 1 mahoney; inactivated poliomyelitis vaccine (d.c.o.) type 2 mef1; inactivated poliomyelitis vaccine (d.c.o.) type 3 saukett - suspension - 20mcg; 20mcg; 5mcg; 3mcg; 15lf; 5lf; 40unit; 8unit; 32unit - pertussis toxoid 20mcg; filamentous haemagglutinin 20mcg; fimbriae 5mcg; pertactin 3mcg; diphtheria toxoid 15lf; tetanus toxoid 5lf; inactivated poliomyelitis vaccine (d.c.o.) type 1 mahoney 40unit; inactivated poliomyelitis vaccine (d.c.o.) type 2 mef1 8unit; inactivated poliomyelitis vaccine (d.c.o.) type 3 saukett 32unit - vaccines

Armenien - engelska - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

sanofi pasteur sa - diphtheria toxoid, tetanus toxoid, pertussis toxoid/filamentous haemagglutinin, poliovirus types 1/2/3, hepatitis b surface antigen, haemophilus infuenzae type b polysaccharide, haemophilus infuenzae type b polysaccharide conjugated to tetanus protein - suspension for injection - 20iu/0.5ml+40iu/0.5ml+25/25mcg/0.5ml+40/8/32 du/0.5ml+10mcg/0.5ml+12mcg/0.5ml+22-36mcg/0.5ml

Armenien - engelska - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

sanofi pasteur sa - diphtheria toxoid, tetanus toxoid, pertussis toxoid/filamentous haemagglutinin, poliovirus types 1/2/3, hepatitis b surface antigen, haemophilus infuenzae type b polysaccharide, haemophilus infuenzae type b polysaccharide conjugated to tetanus protein - suspension for injection - 20iu/0.5ml+40iu/0.5ml+25/25mcg/0.5ml+40/8/32 du/0.5ml+10mcg/0.5ml+12mcg/0.5ml+22-36mcg/0.5ml